Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
FIDIS
94%
Multiplex Immunoassay
94%
Hepatitis B Virus
94%
Infected Patients
94%
Rheumatoid Factor
94%
Anti-cyclic Citrullinated Peptide Antibody (anti-CCP)
71%
Rheumatoid Arthritis
59%
Healthy Volunteers
47%
Portuguese Population
47%
Restriction Fragment Length Polymorphism
47%
Saccharomyces Boulardii
47%
Fibromyalgia
47%
Early Pregnancy Factor
47%
Chlamydia Trachomatis
47%
Active Replication
47%
Randomized Controlled Trial
47%
Human Leukocyte Antigen
47%
Heat Shock Protein 10
47%
Placebo Treatment
47%
Open-label Placebo
47%
Human Herpesvirus
47%
Pilocytic Astrocytoma
47%
Cross-reactivity
47%
Chronic Low Back Pain (cLBP)
47%
Human Leukocyte antigen-DRB1
47%
Human Immunodeficiency Virus Type 1 (HIV-1)
47%
Treatment as Usual
41%
Hepatitis B Virus DNA
28%
Epstein-Barr Virus
23%
Latex Agglutination
23%
Clinical Specificities
23%
Astrocytoma
23%
DNA Polymerase
23%
WaaL
23%
Clinical Sensitivity
23%
Caucasian Patients
18%
HIV Infection
18%
Hepatitis B Virus Infection
18%
Numeric Rating Scale
17%
T Cells
15%
Epitope
15%
B Cells
15%
Point mutation
15%
Direct Sequencing
15%
Cerebellum
15%
Chronic Infection
15%
Viral Infection
15%
Viral mutant
15%
Cell Recognition
15%
HBV Core Antigen
15%
Immunology and Microbiology
ELISA
100%
Human Leukocyte Antigen
94%
Immunoassay
94%
Rheumatoid Factor
94%
Hepatitis B Virus
94%
Inflammatory Arthritis
74%
Antigen-Antibody Interaction
54%
Normal Human
47%
Chlamydia Trachomatis
47%
Replication
47%
Saccharomyces boulardii
47%
HIV Type 1
47%
Restriction Fragment Length Polymorphism
47%
Early Pregnancy Factor
47%
Anti-Citrullinated Protein Antibody
47%
Leukocyte
47%
Virus Core
47%
HIV Type 2
47%
Susceptibility
47%
Cross-Reactivity
47%
Herpesviridae
47%
DNA Polymerase
31%
Infection
27%
Immunoglobulin M
27%
DNA Virus
25%
Neutrophil
23%
Lymphocyte Subpopulation
23%
C3b
23%
Mononuclear Cell
23%
Complement Component C3d
23%
Reticuloendothelial System
23%
Epstein Barr Virus
23%
In Vitro
23%
Complement Component 3
23%
Mitogenesis
23%
Complement System
23%
Acute Phase Protein
23%
Erythrocyte
23%
Phagocytosis
23%
Human immunodeficiency virus
17%
Peptide Antibody
15%
Cerebellum
15%
T Cell
15%
Signal Processing
13%
Immunofluorescence
13%
Microsphere
13%
Hepatitis B
11%
Human Immunodeficiency Virus Infection
11%
Human Immunodeficiency Virus 1
11%
Wild Type
9%
Medicine and Dentistry
Randomized Controlled Trial
47%
Volunteer
47%
Herpesviridae
47%
Low Back Pain
47%
Pilocytic Astrocytoma
47%
Leukocyte
47%
Human Leukocyte Antigen
47%
Fibromyalgia
47%
Placebo
47%
HIV Type 2
47%
HIV Type 1
47%
Hepatitis B Virus
47%
deoxyribonucleic acid nucleotidyl transferase
31%
Virus DNA
25%
Erythrocyte
23%
Phagocytosis
23%
Oligoastrocytoma
23%
In Vitro
23%
Serum Total Protein
23%
Complement Component C3d
23%
Polymorph
23%
Mononuclear Cell
23%
Complement Component C3
23%
Complement System
23%
Complement Component C3b
23%
Reticuloendothelial System
23%
Mitogenesis
23%
Lymphocyte Subpopulation
23%
Epstein Barr Virus
23%
Neutrophil
23%
Combination Therapy
23%
Acute Phase Protein
23%
Serositis
23%
Oral Drug Administration
23%
Human immunodeficiency virus
17%
Numeric Rating Scale
15%
Cerebellum
15%
Carcinogenesis
15%
Hepatitis B
11%
Human Immunodeficiency Virus Infection
11%
Human Immunodeficiency Virus 1
11%
Effect Size
10%
Primary Outcome
10%
Diseases
7%
Human Alphaherpesvirus 1
7%
Gene Dosage
7%
Herpes Simplex Virus 2
7%
Human Herpesvirus 7
7%
Human Herpesvirus 6
7%
Human Herpesvirus 8
7%